These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 23842430)

  • 1. Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response.
    Paran N; Lustig S; Zvi A; Erez N; Israely T; Melamed S; Politi B; Ben-Nathan D; Schneider P; Lachmi B; Israeli O; Stein D; Levin R; Olshevsky U
    Virol J; 2013 Jul; 10():229. PubMed ID: 23842430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host.
    Fang M; Cheng H; Dai Z; Bu Z; Sigal LJ
    Virology; 2006 Feb; 345(1):231-43. PubMed ID: 16256161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epitope mapping by random peptide phage display reveals essential residues for vaccinia extracellular enveloped virion spread.
    He Y; Wang Y; Struble EB; Zhang P; Chowdhury S; Reed JL; Kennedy M; Scott DE; Fisher RW
    Virol J; 2012 Sep; 9():217. PubMed ID: 23006741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An epitope conserved in orthopoxvirus A13 envelope protein is the target of neutralizing and protective antibodies.
    Xu C; Meng X; Yan B; Crotty S; Deng J; Xiang Y
    Virology; 2011 Sep; 418(1):67-73. PubMed ID: 21810533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.
    Xiao Y; Aldaz-Carroll L; Ortiz AM; Whitbeck JC; Alexander E; Lou H; Davis HL; Braciale TJ; Eisenberg RJ; Cohen GH; Isaacs SN
    Vaccine; 2007 Jan; 25(7):1214-24. PubMed ID: 17098336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.
    Clark KM; Johnson JB; Kock ND; Mizel SB; Parks GD
    Virology; 2011 Oct; 419(2):97-106. PubMed ID: 21885079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive Immune Response to Vaccinia Virus LIVP Infection of BALB/c Mice and Protection against Lethal Reinfection with Cowpox Virus.
    Shchelkunov SN; Sergeev AA; Yakubitskiy SN; Titova KA; Pyankov SA; Kolosova IV; Starostina EV; Borgoyakova MB; Zadorozhny AM; Kisakov DN; Shulgina IS; Karpenko LI
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.
    Fogg C; Lustig S; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B
    J Virol; 2004 Oct; 78(19):10230-7. PubMed ID: 15367588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model.
    Chen Z; Earl P; Americo J; Damon I; Smith SK; Yu F; Sebrell A; Emerson S; Cohen G; Eisenberg RJ; Gorshkova I; Schuck P; Satterfield W; Moss B; Purcell R
    J Virol; 2007 Sep; 81(17):8989-95. PubMed ID: 17581986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein.
    Kaever T; Meng X; Matho MH; Schlossman A; Li S; Sela-Culang I; Ofran Y; Buller M; Crump RW; Parker S; Frazier A; Crotty S; Zajonc DM; Peters B; Xiang Y
    J Virol; 2014 Oct; 88(19):11339-55. PubMed ID: 25031354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates.
    Hooper JW; Custer DM; Thompson E
    Virology; 2003 Feb; 306(1):181-95. PubMed ID: 12620810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and Functional Characterization of Anti-A33 Antibodies Reveal a Potent Cross-Species Orthopoxviruses Neutralizer.
    Matho MH; Schlossman A; Meng X; Benhnia MR; Kaever T; Buller M; Doronin K; Parker S; Peters B; Crotty S; Xiang Y; Zajonc DM
    PLoS Pathog; 2015 Sep; 11(9):e1005148. PubMed ID: 26325270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The generation of CD8+ T-cell population specific for vaccinia virus epitope involved in the antiviral protection against ectromelia virus challenge.
    Gierynska M; Szulc-Dabrowska L; Dzieciatkowski T; Golke A; Schollenberger A
    Pathog Dis; 2015 Dec; 73(9):ftv088. PubMed ID: 26474845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.
    Yang G; Pevear DC; Davies MH; Collett MS; Bailey T; Rippen S; Barone L; Burns C; Rhodes G; Tohan S; Huggins JW; Baker RO; Buller RL; Touchette E; Waller K; Schriewer J; Neyts J; DeClercq E; Jones K; Hruby D; Jordan R
    J Virol; 2005 Oct; 79(20):13139-49. PubMed ID: 16189015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
    Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
    J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.
    Kaufman DR; Goudsmit J; Holterman L; Ewald BA; Denholtz M; Devoy C; Giri A; Grandpre LE; Heraud JM; Franchini G; Seaman MS; Havenga MJ; Barouch DH
    J Virol; 2008 Jul; 82(14):6829-37. PubMed ID: 18448519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.
    Braxton CL; Puckett SH; Mizel SB; Lyles DS
    J Virol; 2010 Apr; 84(7):3552-61. PubMed ID: 20089648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phage display antibodies against ectromelia virus that neutralize variola virus: Selection and implementation for p35 neutralizing epitope mapping.
    Khlusevich Y; Matveev A; Baykov I; Bulychev L; Bormotov N; Ilyichev I; Shevelev G; Morozova V; Pyshnyi D; Tikunova N
    Antiviral Res; 2018 Apr; 152():18-25. PubMed ID: 29427674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterotypic immunity against vaccinia virus in an HLA-B*07:02 transgenic mousepox infection model.
    Kumar A; Suryadevara NC; Wolf KJ; Wilson JT; Di Paolo RJ; Brien JD; Joyce S
    Sci Rep; 2020 Aug; 10(1):13167. PubMed ID: 32759969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara.
    Volz A; Langenmayer M; Jany S; Kalinke U; Sutter G
    J Virol; 2014 Sep; 88(18):10946-57. PubMed ID: 25008931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.